STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib
Overview
Overview
Journal
J Clin Immunol
Publisher
Springer
Specialty
Allergy & Immunology
Date
2023 Mar 7
PMID
36881346
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function.
Kaneko S, Sakura F, Tanita K, Shimbo A, Nambu R, Yoshida M Immunother Adv. 2024; 3(1):ltad027.
PMID: 38549698 PMC: 10977912. DOI: 10.1093/immadv/ltad027.
References
1.
Deya-Martinez A, Riviere J, Roxo-Junior P, Ramakers J, Bloomfield M, Guisado Hernandez P
. Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature. J Clin Immunol. 2022; 42(5):1071-1082.
PMC: 9402491.
DOI: 10.1007/s10875-022-01257-x.
View
2.
Sabat R, Jemec G, Matusiak L, Kimball A, Prens E, Wolk K
. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020; 6(1):18.
DOI: 10.1038/s41572-020-0149-1.
View
3.
Shi J, Chen X, Lee F, Emm T, Scherle P, Lo Y
. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014; 54(12):1354-61.
DOI: 10.1002/jcph.354.
View
4.
Rumberger B, Boarder E, Owens S, Howell M
. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. Inflamm Res. 2020; 69(10):967-973.
DOI: 10.1007/s00011-020-01381-7.
View
5.
Guisado Hernandez P, Lobo P, Villaoslada I, De Felipe B, Lucena J, Martin Gutierrez G
. SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?. J Clin Immunol. 2021; 41(7):1502-1506.
PMC: 8189704.
DOI: 10.1007/s10875-021-01081-9.
View